Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Phase of Trial: Phase II
Latest Information Update: 01 May 2017
At a glance
- Drugs Valsartan (Primary)
- Indications Cardiomyopathies
- Focus Therapeutic Use
- Acronyms VANISH
- 01 May 2017 Trial Design published in the American Heart Journal.
- 05 Oct 2015 Planned End Date changed from 1 Mar 2017 to 1 Nov 2018 as reported by ClinicalTrials.gov record.
- 05 Oct 2015 Planned primary completion date changed from 1 Mar 2017 to 1 Nov 2018 as reported by ClinicalTrials.gov record.